Current Status
Not Enrolled
Price
Free
Get Started
Course
Resources
Information

Eosinophilic Granulomatosis with Polyangiitis (EGPA) Diagnostic Challenges

Program: Managing Individuals with EGPA
To obtain CME/CE credit, you must LOG-IN and ENROLL (click orange button at top of page)

Provided by

This educational activity is supported by an educational grant from GlaxoSmithKline.

Course Description

Unfortunately, many clinicians may encounter individuals who are living with undiagnosed EGPA. Although these patients could gain benefit from treatment, damage has often already occurred by the time a diagnosis is made and patients have unnecessarily suffered in the interim. Early consideration of EGPA disease in the differential diagnosis could allow individuals to be diagnosed earlier and gain maximal quality of life with effective therapy.

The goal of this educational initiative is to improve the knowledge and ability of clinicians who may encounter individuals with EGPA to recognize, manage, and treat patients with EGPA.

Learning Objective

After participating in the activity, learners should be better able to:

  • Identify strategies for overcoming challenges to diagnosing EGPA disease

Release date: 10/31/19
Expiration date: 10/31/20
Estimated time to complete: 0.25 hours

Activity Faculty

Michael E. Wechsler, MD, MMSc
Professor of Medicine
Director, Cohen Family NJH Asthma Institute
Director, Asthma Program, National Jewish Health
Division of Pulmonary, Critical Care and Sleep Medicine
Department of Medicine
National Jewish Health and
University of Colorado School of Medicine

Target Audience

This program is intended for pulmonologists, allergists, rheumatologists, neurologists, dermatologists, cardiologists, gastroenterologists, and nephrologists. Other members of the care team, including nurse practitioners and PAs, may also participate.

Accreditation and Credit Designation

In support of improving patient care, American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the brief post assessment and evaluation. Your certificate can be available immediately.

Disclosure Statement

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosures are as follows:

Faculty Educator

Michael Wechsler, MD, MMSc discloses the following relationships with commercial interests:
Consultant – for marketing purposes: Sanofi, AstraZeneca, Novartis, Regeneron, GlaxoSmithKline, Genentech, Novartis, Teva, Mylan
Consultant – for clinical trial design: Sanofi, AstraZeneca, Novartis, Regeneron, Equillium, Restorbio, Pulmatrix, GALA Therapeutics

Planning Committee

Activity planners have no relevant financial relationships with any commercial interests to disclose.

Disclaimer

This activity may contain discussion of off-label or investigational information.

The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

Hardware/Software Requirements

Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection

Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection

Privacy

For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm

For more information about CheckRare’s privacy policy, please access https://checkrare.com/privacy/

Contact

For any questions, please contact: CEServices@academycme.org

Copyright

© 2019. This CME-certified activity is held as copyrighted © by American Academy of CME, Inc and CheckRare CE, Inc.. Through this notice, the two organizations grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

Eosinophilic Granulomatosis with Polyangiitis (EGPA) Diagnostic Challenges

Program: Managing Individuals with EGPA

Slides

EGPA Diagnostic Challenges Module 3 slides

Resources

  • Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951;27:277-301.
  • Jennette JC, Falk RJ, Bacon PA. et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthr Rheum. 2013;65:1-11.
  • Furuta S, Iwamoto T, Nakajima H. Update on eosinophilic granulomatosis with polyangiitis. Allergol Int. 2019;68:430-436.
  • Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med. 2015;26:545-553.
  • Gioffredi A, Maritati F, Oliva E, Buzio C. Eosinophilic granulomatosis with
    polyangiitis: an overview. Front Immunol. 2014;5:549
  • Chakraborty RK, Aeddula NR. Churg Strauss Syndrome (Allergic Granulomatosis). 2019 Jun 4. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK537099/
  • Yasir M, Sonthalia S. Corticosteroid Adverse Effects. 2019 Mar 24. StatPearls
    [Internet]. Treasure Island (FL): StatPearls Publishing.
    http://www.ncbi.nlm.nih.gov/books/NBK531462/
  • Dan D, Fischer R, Adler S. Forger F, Villiger PM. Cyclophosphamide: as bad as its reputation? Eur J Med Sci. 2014;144:w14030
  • Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 2017;376:1921-1932.

Eosinophilic Granulomatosis with Polyangiitis (EGPA) Diagnostic Challenges

Program: Managing Individuals with EGPA

Provided by

This educational activity is supported by an educational grant from GlaxoSmithKline.

Course Description

Unfortunately, many clinicians may encounter individuals who are living with undiagnosed EGPA. Although these patients could gain benefit from treatment, damage has often already occurred by the time a diagnosis is made and patients have unnecessarily suffered in the interim. Early consideration of EGPA disease in the differential diagnosis could allow individuals to be diagnosed earlier and gain maximal quality of life with effective therapy.

The goal of this educational initiative is to improve the knowledge and ability of clinicians who may encounter individuals with EGPA to recognize, manage, and treat patients with EGPA.

Learning Objective

After participating in the activity, learners should be better able to:

  • Identify strategies for overcoming challenges to diagnosing EGPA disease

Release date: 10/31/19
Expiration date: 10/31/20
Estimated time to complete: 0.25 hours

Activity Faculty

Michael E. Wechsler, MD, MMSc
Professor of Medicine
Director, Cohen Family NJH Asthma Institute
Director, Asthma Program, National Jewish Health
Division of Pulmonary, Critical Care and Sleep Medicine
Department of Medicine
National Jewish Health and
University of Colorado School of Medicine

Target Audience

This program is intended for pulmonologists, allergists, rheumatologists, neurologists, dermatologists, cardiologists, gastroenterologists, and nephrologists. Other members of the care team, including nurse practitioners and PAs, may also participate.

Accreditation and Credit Designation

In support of improving patient care, American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the brief post assessment and evaluation. Your certificate can be available immediately.

Disclosure Statement

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosures are as follows:

Faculty Educator

Michael Wechsler, MD, MMSc discloses the following relationships with commercial interests:
Consultant – for marketing purposes: Sanofi, AstraZeneca, Novartis, Regeneron, GlaxoSmithKline, Genentech, Novartis, Teva, Mylan
Consultant – for clinical trial design: Sanofi, AstraZeneca, Novartis, Regeneron, Equillium, Restorbio, Pulmatrix, GALA Therapeutics

Planning Committee

Activity planners have no relevant financial relationships with any commercial interests to disclose.

Disclaimer

This activity may contain discussion of off-label or investigational information.

The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

Hardware/Software Requirements

Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection

Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection

Privacy

For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm

For more information about CheckRare’s privacy policy, please access https://checkrare.com/privacy/

Contact

For any questions, please contact: CEServices@academycme.org

Copyright

© 2019. This CME-certified activity is held as copyrighted © by American Academy of CME, Inc and CheckRare CE, Inc.. Through this notice, the two organizations grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

  • Sign up
Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.
We do not share your personal details with anyone.